PYRROLOPYRIDINES EFFECTIVE AS PROTEINKINASE INHIBITORS Russian patent published in 2011 - IPC C07D471/04 C07D487/04 A61K31/437 A61K31/4353 A61K31/444 A61K31/4545 A61K31/4725 A61K31/496 A61K31/506 A61K31/517 A61K31/519 A61K31/551 A61P35/00 

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to a compound of formula (I): or its pharmaceutically acceptable salt where Q is 2,6-pyrimidyl; where Q is optionally substituted by 1-5 substitutes J^Q; Z is a link or NH; R¹ is H; R² is H; R³ is halogen or -(U)_m-X where m is equal to 0; X is H or halogen; J^Q is halogen, OCF₃, -(V_n)-R", -(V_n)-CN or -(V_n)-(C_1-4 halogenaliphatic group) where J^Q is not H; V is C_1-10aliphatic group where up to three methylene groups are substituted by G^V where G^v is selected from -NH-, -NR-, -O-, -S-, -CO₂-, -C(O)CO-, -C(O), -C(O)NH-, -C(O)NR-, -C(=N-CN)-, -NHCO-, -NRCO-, -NHSO₂-, -NRSO₂-, -NHC(O)NH-, -NRC(O)NH-, -NHC(O)NR-, -NRC(O)NR or -SO₂-; and where V is optionally substituted by 1-6 substitutes J^V; R" is H or an optionally substituted group selected from C_1-6aliphatic group, C_3-10cycloaliphatic group, C_6-10aryl, 5-10-member heteroaryl or 5-10-member heterocyclyl; or two R" groups on the same substitute or various substitutes together with atom (s) whereto each group R" is attached, form optionally substituted 3-8-member heterocyclyl; where each optionally substituted R" group is independently and optionally substituted by 1-6 substitutes J^R; R is an optionally substituted group selected from C_1-6aliphatic group and C_6-10aryl where each group R is independently and optionally substituted by 1-4 substitutes J^R; each J^v and J^R are independently selected from halogen, L, - (L_n)-R', - (L_n)-N(R')₂, -(L_n)-OR', C_1-4haloalkyl, -(L_n)-CN, - (L_n)-OH, -CO₂R', -CO₂H or -COR'; or two J^v, J^R groups on the same substitute or various substitutes together with atom (s) whereto each group J^V and J^R is attached, form a 5-7-member saturated, unsaturated or partially saturated ring; R' is H or C_1-6aliphatic group; L is C_1-6aliphatic group where up to three methylene units are substituted by -C(O)-; each n is independently equal to 0 or 1. Besides, an invention refers to of a pharmaceutical composition for ROCK or JAK kinase inhibition on the basis of the given compounds, to a method of ROCK or JAK kinase activity inhibition, and also to application of the compounds of formula I, for preparing a drug where Q, Z, R¹, R² and R³ are those as described in cl. 1 of the patent claim, effective as protein kinase inhibitors, especially JAK and ROCK families kinase inhibitors.

EFFECT: there are prepared and described new compounds which can find the application in medicine.

42 cl, 6 tbl, 5 ex